TY - JOUR
T1 - The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression
AU - Gao, Dingcheng
AU - Mittal, Vivek
N1 - Funding Information:
The authors thank Kevin McDonnell and Mary Hahn for critical comments and several other investigators for sharing their unpublished work. We acknowledge that space constraints might have precluded the citation of work by some investigators. The author was supported by grants from National Institute of Health and the Robert Goldman Foundation.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/8
Y1 - 2009/8
N2 - Emerging evidence from murine models suggests that tumor-specific endocrine factors systemically stimulate the quiescent bone marrow (BM) compartment, resulting in the expansion, mobilization and recruitment of BM progenitor cells. Discrete subsets of tumor-instigated BM-derived progenitor cells support tumor progression and metastasis by regulating angiogenesis, inflammation and immune suppression. Notably, clinical studies have begun to reveal that increased BM recruitment in tumors is associated with poor prognosis. Thus, the BM-derived tumor microenvironment is an attractive therapeutic target, and drugs targeting the components of the microenvironment are currently in clinical trials. Here, we focus on recent advances and emerging concepts regarding the intriguing role of BM-derived cells in tumor growth, metastasis initiation and progression, and we discuss future directions in the context of novel diagnostic and therapeutic opportunities.
AB - Emerging evidence from murine models suggests that tumor-specific endocrine factors systemically stimulate the quiescent bone marrow (BM) compartment, resulting in the expansion, mobilization and recruitment of BM progenitor cells. Discrete subsets of tumor-instigated BM-derived progenitor cells support tumor progression and metastasis by regulating angiogenesis, inflammation and immune suppression. Notably, clinical studies have begun to reveal that increased BM recruitment in tumors is associated with poor prognosis. Thus, the BM-derived tumor microenvironment is an attractive therapeutic target, and drugs targeting the components of the microenvironment are currently in clinical trials. Here, we focus on recent advances and emerging concepts regarding the intriguing role of BM-derived cells in tumor growth, metastasis initiation and progression, and we discuss future directions in the context of novel diagnostic and therapeutic opportunities.
UR - http://www.scopus.com/inward/record.url?scp=68649089967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68649089967&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2009.06.006
DO - 10.1016/j.molmed.2009.06.006
M3 - Article
C2 - 19665928
AN - SCOPUS:68649089967
SN - 1471-4914
VL - 15
SP - 333
EP - 343
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 8
ER -